핵의학 시장 : 제품 유형, 투여 방법, 용도, 응용 분야, 최종 사용자별 예측(2026-2032년)

The Nuclear Medicine Market is projected to grow by USD 23.88 billion at a CAGR of 9.36% by 2032.

Nuclear medicine is moving from a primarily diagnostic specialty toward an integrated precision medicine platform that combines PET/CT, SPECT/CT, radiopharmaceutical therapy, companion diagnostics, and patient-specific dosimetry. The field benefits from strong clinical demand in oncology, cardiology, neurology, endocrinology, and infection imaging, with technetium-99m remaining the workhorse for SPECT and fluorine-18, gallium-68, copper-64, zirconium-89, iodine-131, lutetium-177, and actinium-225 supporting higher-value diagnostic and therapeutic use cases.

Verified public health data reinforces the long-term need for nuclear medicine services. The WHO/IARC GLOBOCAN 2022 database reported about 20 million new cancer cases and 9.7 million cancer deaths worldwide, while WHO estimates more than 55 million people live with dementia globally. Cardiovascular disease also remains the leading cause of death worldwide, according to WHO, supporting sustained demand for myocardial perfusion imaging, molecular imaging, radiotracer development, targeted radionuclide therapy, and scalable radiopharmacy infrastructure.

Transformative Shifts in the Nuclear Medicine Landscape

The most important shift in the nuclear medicine landscape is the rise of theranostics, where the same biological target is used for diagnosis, patient selection, therapy, and response monitoring. FDA approvals such as lutetium Lu-177 dotatate for somatostatin receptor-positive neuroendocrine tumors and lutetium Lu-177 vipivotide tetraxetan for PSMA-positive prostate cancer have validated clinical and commercial models for targeted radiopharmaceutical therapy.

At the same time, supply chain resilience has become a strategic priority. Molybdenum-99 and technetium-99m availability depends on a limited global production network, while short half-life PET isotopes require localized cyclotron, generator, or distribution capacity. Hospitals, radiopharmacies, and manufacturers are therefore investing in generator networks, automated synthesis, quality control systems, cold-kit innovation, workforce training, and regional isotope production to reduce disruption risk and improve patient access.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of nuclear medicine by improving image reconstruction, attenuation correction, lesion detection, organ segmentation, quantitative PET/SPECT analysis, and workflow prioritization. The FDA public list of AI/ML-enabled medical devices includes hundreds of cleared products, with radiology representing the largest category, demonstrating regulatory acceptance of algorithm-supported imaging workflows.

In nuclear medicine, AI is especially relevant because quantitative accuracy directly affects staging, therapy selection, and dosimetry. AI-enabled tools can reduce scan time, support low-dose protocols, harmonize multi-center trial data, assist PSMA and somatostatin receptor lesion assessment, and automate absorbed-dose calculations for radionuclide therapy. The cumulative impact is a shift from visual interpretation toward reproducible, data-rich molecular imaging that supports precision oncology, clinical trial efficiency, and value-based care.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America remains a leading nuclear medicine region due to advanced PET/CT adoption, a strong FDA pathway for radiopharmaceutical approvals, established reimbursement for many nuclear imaging procedures, and active clinical trial networks in prostate cancer, neuroendocrine tumors, cardiology, and neurology. Europe combines mature hospital infrastructure with EMA oversight, European Association of Nuclear Medicine clinical guidance, and strong radiopharmaceutical research, while European Union cross-border regulatory coordination and isotope initiatives support standardization and supply security.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in cancer centers, cyclotrons, PET/CT capacity, and domestic isotope capabilities to address rising oncology, cardiovascular, and neurological disease burdens. Latin America, led by Brazil and Mexico, shows rising demand but faces uneven access to cyclotrons, radiopharmacies, trained specialists, and reimbursement. The Middle East is building specialized oncology and diagnostic imaging capacity through hospital modernization programs, particularly in GCC countries, while Africa remains underpenetrated, with IAEA support, national cancer control initiatives, and public-sector hospital investment playing important roles in expanding access to radiopharmaceutical services.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

The G7 countries anchor a large share of high-value nuclear medicine adoption because they combine advanced hospital infrastructure, regulatory capacity, isotope production expertise, academic trial networks, and reimbursement systems that support PET/CT, SPECT/CT, and radiopharmaceutical therapy. NATO markets overlap significantly with North American and European healthcare systems, where nuclear medicine supports military, veteran, and civilian healthcare through oncology imaging, cardiac perfusion imaging, bone scintigraphy, and infection evaluation.

The European Union is central to radiopharmaceutical regulation, research funding, clinical standardization, and medical isotope supply security discussions. BRICS countries are becoming increasingly important because Brazil, Russia, India, China, and South Africa represent large patient populations, nuclear science capabilities, and rising oncology investment. ASEAN countries are improving PET/CT and SPECT access as urban tertiary care expands, while the GCC is investing in premium hospital infrastructure, cancer care, advanced diagnostic imaging, and regional radiopharmacy capabilities to reduce dependence on imported services.

Key Country Insights Across Major Nuclear Medicine Markets

The United States leads in radiopharmaceutical innovation, FDA-approved theranostics, PET imaging, and clinical development, while Canada contributes isotope expertise, cyclotron networks, and academic nuclear medicine research. Mexico and Brazil are important Latin American markets where expanding oncology capacity supports PET/CT and SPECT demand. The United Kingdom, Germany, France, Italy, and Spain maintain mature nuclear medicine networks, and Germany and France are particularly influential in radiopharmaceutical research, manufacturing, clinical guidance, and hospital-based adoption.

Russia retains nuclear science and isotope capabilities, while China and India are scaling imaging capacity to meet large cancer and cardiovascular disease burdens. Japan and South Korea combine advanced imaging adoption with strong technology ecosystems, and Australia is notable for theranostics leadership, nuclear medicine training, and regional clinical research. Across the United States, Canada, Mexico, Brazil, the United Kingdom, Germany, France, Russia, Italy, Spain, China, India, Japan, Australia, and South Korea, access depends on reimbursement, isotope logistics, specialist workforce availability, radiation safety infrastructure, and hospital investment in PET/CT, SPECT/CT, cyclotrons, generators, and radiopharmacy systems.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize theranostic portfolio development, secure isotope sourcing, and differentiated radiopharmaceutical manufacturing capabilities. Partnerships with hospitals, cyclotron operators, generator suppliers, academic centers, and contract development and manufacturing organizations can reduce capacity bottlenecks and accelerate clinical adoption.

Commercial success also requires evidence generation beyond regulatory approval. Organizations should invest in real-world outcomes, health economics, dosimetry validation, AI-enabled quantification, clinician education, multidisciplinary tumor boards, and patient referral pathways. Building resilient cold-chain logistics, automated quality control, radiation safety programs, and reimbursement dossiers will be essential for scaling nuclear medicine from specialized centers to broader oncology and diagnostic networks.

Research Methodology

This executive summary is built from publicly verifiable secondary research and cross-validated industry intelligence. Core sources include WHO, IARC GLOBOCAN, IAEA, OECD, FDA, EMA, EANM, SNMMI, national health agencies, peer-reviewed clinical literature, regulatory approval databases, and publicly available institutional disclosures.

The methodology applies triangulation across disease burden, procedure demand, isotope availability, radiopharmaceutical approvals, technology adoption, reimbursement conditions, and regional infrastructure. Market interpretation focuses on verified indicators rather than unsupported estimates, with emphasis on clinical utility, supply chain feasibility, regulatory pathways, radiation safety, and commercialization readiness across nuclear medicine diagnostics and therapeutics.

Conclusion

Nuclear medicine is entering a high-value clinical growth phase driven by precision oncology, theranostics, AI-enabled imaging, and the need for earlier, more accurate disease characterization. Clinical validation of PSMA-targeted and somatostatin receptor-targeted radiopharmaceuticals has shifted the sector from niche imaging toward integrated diagnosis, therapy selection, and response monitoring.

The strongest opportunities will favor organizations that can combine scientific credibility, isotope security, manufacturing quality, data-driven workflows, radiation safety, and regional market access. As cancer, cardiovascular disease, and neurodegenerative disorders continue to create global healthcare pressure, nuclear medicine is positioned to become a core pillar of personalized diagnosis, treatment planning, and long-term patient management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Nuclear Medicine Market, by Product Type

• 7.1. Diagnostic Radiopharmaceuticals
  • 7.1.1. Positron Emission Tomography (PET) Isotopes
  • 7.1.2. Single Photon Emission Computed Tomography (SPECT) Isotopes
• 7.2. Therapeutic Nuclear Medicine
  • 7.2.1. Brachytherapy Isotopes
    • 7.2.1.1. Cesium-131
    • 7.2.1.2. Iodine-125
    • 7.2.1.3. Iridium-192
    • 7.2.1.4. Palladium-103
  • 7.2.2. Radiopharmaceutical Therapy
    • 7.2.2.1. Alpha Emitters
    • 7.2.2.2. Beta Emitters

8. Nuclear Medicine Market, by Mode Of Administration

• 8.1. Intravenous Injection
• 8.2. Oral Ingestion

9. Nuclear Medicine Market, by Usage

• 9.1. Diagnostic Procedure
  • 9.1.1. PET Scanners
    • 9.1.1.1. Analog PET
    • 9.1.1.2. Digital PET
  • 9.1.2. SPECT Scanners
• 9.2. Therapeutic Procedure

10. Nuclear Medicine Market, by Application

• 10.1. Cardiology
• 10.2. Endocrinology
• 10.3. Gastroenterology
• 10.4. Neurology
• 10.5. Oncology
• 10.6. Orthopedics
• 10.7. Pulmonology

11. Nuclear Medicine Market, by End Users

• 11.1. Academic & Research Institutes
• 11.2. Diagnostic Centers
• 11.3. Hospitals
  • 11.3.1. Government Hospitals
  • 11.3.2. Private Hospitals

12. Nuclear Medicine Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Nuclear Medicine Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Nuclear Medicine Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 3B Pharmaceuticals GmbH
• 16.2. Actinium Pharmaceuticals, Inc.
• 16.3. B J Madan & Co.
• 16.4. Bayer AG
• 16.5. Bracco S.p.A.
• 16.6. BWX Technologies, Inc.
• 16.7. Clarity Pharmaceuticals
• 16.8. Curium
• 16.9. Eli Lilly and Company
• 16.10. GE HealthCare
• 16.11. IBA
• 16.12. Institute of Isotopes Co., Ltd
• 16.13. Isotopia Molecular Imaging Ltd.
• 16.14. Jubilant Pharma Limited
• 16.15. Lantheus Holdings, Inc.
• 16.16. Medi-Radiopharma Co., Ltd.
• 16.17. Nordion
• 16.18. Northstar Medical Technologies LLC
• 16.19. Novartis AG
• 16.20. Nusano, Inc.
• 16.21. PeptiDream Inc.
• 16.22. Radiopharm Theranostics Limited
• 16.23. SHINE Technologies, LLC
• 16.24. Siemens Healthineers AG
• 16.25. Sinotau Pharmaceuticals Group
• 16.26. South African Nuclear Energy Corporation
• 16.27. State Atomic Energy Corporation Rosatom
• 16.28. Thor Medical AS by Nordic Nanovector ASA